Elafibranor

Aug 06, 2018

IQ4I Research and Consultancy Published New Pipeline Analysis on 'Non-Alcoholic SteatoHepataitis (NASH)'

Aug 03, 2018

Data Projects the NASH Market Will Eclipse USD 21 Billion by 2025

Jul 31, 2018

Non-Alcoholic Steatohepatitis (NASH) Market to Witness a CAGR of 58.4% During 2021 to 2025 - Allied Market Research

Jan 04, 2018

Spitfire Pharma's SP-1373 outscored semaglutide and elafibranor in a biopsy-proven translational mouse model of non-alcoholic steatohepatitis (NASH)

Oct 24, 2017

Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

Oct 10, 2017

Non-Alcoholic Steatohepatitis Drugs Market (NASH) Trends, Size, Growth, Opportunities and 2026 Forecast Report

Sep 11, 2017

Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)

Jun 06, 2017

Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)